Pamela Vig, Ph.D.
Pamela Vig, Ph.D. joined Mirum in 2018 as chief scientific officer and was promoted in 2021 to head of R&D where she leads the scientific and clinical aspects of drug development and research, and medical affairs.
Pam has more than 25 years of industry experience in clinical development, medical affairs and translational science in various liver diseases including hepatitis B (HBV), hepatitis C (HCV), nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and cholestatic liver disease, as well as HIV and other infectious diseases. Before joining Mirum, Pam held leadership roles at Allergan plc and Tobira Therapeutics as vice president of clinical research and discovery, as well as vice president of clinical research at Presidio Pharmaceuticals, Inc. Pam previously served as director, global medical affairs, at Johnson & Johnson in London, UK, and also held positions in clinical research and development at Idenix Pharmaceuticals and Gilead Sciences, Inc. Pam is a member of the PSC Forum Steering Committee as well as co-chair for the pediatric cholestatic disease working group under the Forum for Collaborative Research.
Pam holds a Ph.D. from Imperial College London in the departments of hepatology and histopathology.